Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Canada supplies Ebola treatment to Spain, Norway

15 October 2014, 19:30

Winnipeg - Canada has supplied small amounts of an experimental Ebola treatment to Spain and Norway to treat infected healthcare workers, the Public Health Agency of Canada said on Wednesday.

The agency's National Microbiology Laboratory in Winnipeg, Manitoba transferred the treatment ZMAb to Spain in September and to Norway this month, at the request of the countries, spokesman Robert Cyrenne said. The treatment is laboratory grade, meaning it was made for use on animals.

A nurse remained seriously ill this week after catching the virus in Madrid while caring for infected patients. A Norwegian healthcare worker working for Doctors Without Borders in Sierra Leone was infected and brought home for treatment, the organization said last week.

At least 4,447 people have died in West Africa in the worst Ebola outbreak on record.

ZMAb is a monoclonal antibody treatment designed to find, attach and coat the Ebola virus, preventing it from multiplying within the body.

Also read: 2nd Texas healthcare worker contracts Ebola

The treatment is a precursor to ZMapp, which Canada licensed to California-based Mapp Biopharmaceutical Inc. ZMapp was used this summer to treat two American aid workers, who recovered.

Another experimental drug developed in Canada by Tekmira Pharmaceuticals Corp was used last month on an infected U.S. medical missionary, who also recovered.

The Public Health Agency sent enough ZMAb for Spain and Norway to each treat one person and plans to keep all remaining inventory in Canada for research or possible domestic use.

Meanwhile, the World Health Organization has not yet received Canada's donation of 800 doses of an experimental Ebola vaccine. Cyrenne and WHO spokeswoman Nyka Alexander could not immediately say when Canada would ship the vaccine to WHO in Geneva.

Phase 1 clinical trials of the vaccine on a small group of people are underway in the United States, with results expected in December. Canada has licensed the commercial rights to the vaccine to NewLink Genetics Corp.

- Reuters

Tags zmapp ebola

Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...